UnitedHealth Group Incorporated (UNH)

1. Executive snapshot

2. What the company does

The customer problem is unpredictable medical spending. An employer, a state Medicaid programme or the federal Medicare programme would rather pay a known amount per person each month than carry the risk that a few members need cancer care or a transplant. UnitedHealthcare takes that risk for a fixed premium, usually set for one year, or administers a self-funded plan for a fee while the employer keeps the risk (FY2025 10-K). Premiums were 78.7% of 2025 revenue (derived). Premiums from CMS alone equalled 44% of revenue, up from 25% in 2016 (FY2025 and FY2016 10-K).

The unit of economics is one risk member-month. The company does not disclose premium per member, so these figures are derived: $332.4 billion of 2025 UnitedHealthcare premiums over an average 28.4 million risk members gives about $976 per member per month (FY2025 10-K, derived). The spread is wide. A Medicaid member brings about $1,062 a month, a commercial risk member about $643, and a self-funded (ASO) member about $41 of fees with no medical risk attached (derived). Fee-based members are now 72.5% of commercial members and still growing, which makes the commercial book safer and less lucrative per head.

Follow one Medicare Advantage member-month. CMS pays a monthly premium adjusted for the member's recorded diagnoses and for the plan's Star rating; only plans rated four stars or above earn bonus payments (FY2025 10-K). Claims arrive over the following weeks and about 90% are settled within 90 days. At any moment the company therefore holds the money for care already delivered but not yet paid: medical costs payable were $39.3 billion at end-2025, of which $26.7 billion was an estimate of claims incurred but not reported (FY2025 10-K). That float is why operating cash flow has averaged about 1.4 times net earnings since 2016 (derived).

If the member sees an Optum physician under a value-based contract, UnitedHealthcare passes a share of the premium to Optum Health, which then carries the cost of care. Prescriptions run through Optum Rx, and the claim may be processed on Optum Insight software. In 2025, $168.0 billion, or 48.7% of UnitedHealthcare's revenue, flowed to Optum in this way, up from 31.9% in 2016; 62.1% of Optum's revenue came from inside the group (FY2025 and FY2016 10-K, derived). Optum produced 50.3% of 2025 earnings from operations (derived).

The portfolio has been cut back to what the company can manage. It sold its Brazilian operations in February 2024 at a $7.1 billion loss including currency translation, agreed to sell the rest of South America (closing expected in the second half of 2026) and sold its U.K. business in 2026 (FY2025 10-K; Q2 2026 10-Q; Q1 2026 call). In the U.S. it dropped Medicare Advantage plans covering more than 600,000 members, mostly loosely managed PPOs, left one Medicaid state, and narrowed Optum Health's affiliated physician network by nearly 20% (Q2 2025 and Q4 2025 calls). The common thread is exiting business where it cannot control the cost of care: foreign health systems with currency and policy exposure, and open-network plans where utilisation is hard to manage.

3. Industry, competitive position & moat

Managed care exists to pool medical risk and administer the money that pays for care. U.S. health spending was $5.3 trillion in 2024, 18.0% of GDP. Private insurance paid $1.64 trillion, Medicare $1.12 trillion and Medicaid $0.93 trillion [web: CMS National Health Expenditure data]. Most of that passes through insurers to hospitals, physicians and drug makers. Minimum medical-loss-ratio rules make insurers rebate premium when spending on care falls below set targets (FY2025 10-K), so the insurance layer's profit is capped by design. The U.S. health insurance industry earned a 0.4% net margin in 2025, down from 0.8%, on a 90.3% loss ratio [web: NAIC].

The relevant market is local and product by product. Medicare Advantage is sold county by county, Medicaid through state contracts, commercial insurance employer by employer. UnitedHealthcare and Humana held about 46% of Medicare Advantage enrolment in 2025, and UnitedHealthcare was the largest MA insurer in 41% of counties in 2024 [web: KFF]. Pharmacy benefit management is a national oligopoly: Express Scripts, CVS Caremark and Optum Rx processed about 80% of U.S. prescription claims in 2025, with Optum Rx at 23% [web: Drug Channels, via Becker's].

The barriers that bind are scale in claims data and provider contracts, statutory capital and Star ratings. A new insurer needs capital held in regulated subsidiaries (UnitedHealth's were required to hold about $23.2 billion at end-2025, FY2025 10-K), years of claims history to price risk, and four-star scores to earn bonuses. These barriers do not stop incumbents taking share from each other. Humana added about 1.3 million MA members for 2026 while UnitedHealth's MA share fell from 29% to 26% [web: Becker's citing KFF, secondary]. Members can switch plans every year, so the moat is the ability to price and manage cost, not customer captivity.

UnitedHealth's specific position is vertical integration at scale. No rival combines the largest MA book with a physician business serving 95 million consumers, a top-three PBM managing $188 billion of drug spend, and the Change Healthcare claims network (FY2025 10-K). A well-funded competitor could buy any one piece. Reproducing the internal flow of $168 billion a year would take a decade of deals, which is how UnitedHealth built it: $80.0 billion of acquisition cash from 2016 to 2025 (derived). The same integration draws regulators. MedPAC estimates MA payments ran about 14% above traditional Medicare for similar enrollees in 2026, about 4 points of it from coding intensity [web: MedPAC], and Medicare coding is what the DOJ is examining at UnitedHealth (8-K, July 24, 2025).

Claims tested. "Competitive medical and operating cost positions" (FY2025 10-K) is partially supported: the 2025 medical care ratio was in line with Elevance and Humana and better than CVS, but worse than commercial-heavy Cigna [web], and the 10-K itself says 2025 pricing was "well-short" of the trend incurred. Market leadership in MA is supported but eroding. The claim that owning care delivery lowers cost is contradicted for now: Optum Health lost $278 million in 2025 after earning $7.8 billion in 2024, with value-based margins near 1% (FY2025 10-K; Q3 2025 call).

The company that wins in managed care prices next year's medical trend accurately, manages utilisation tightly and keeps its government payers on side. UnitedHealth was that company for most of the decade, with a medical care ratio of 79–83% from 2016 to 2023. It failed the first test in 2025 and is under scrutiny on the third. Whether 2025 was a lapse or a lasting loss of edge is the central open question.

4. Growth engine

Revenue grew from $184.8 billion in 2016 to $447.6 billion in 2025, 10.3% a year (derived). Three things did it. Medicare Advantage members rose from 3.6 million to 8.4 million. Revenue per member rose with medical costs and government payments; Medicaid revenue per member roughly doubled (derived). And Optum took a growing share of each premium dollar. Earnings lagged at the end: earnings from operations compounded at 12.1% to 2024 but 4.3% to 2025 (derived). Adjusted EPS went from $8.05 in 2016 to $27.66 in 2024 and back to $16.35 in 2025, 8.2% a year over the full period (company proxies, derived).

Organic growth is not disclosed. Each 10-K calls acquired revenue immaterial, yet the company spent $80.0 billion on acquisitions over the decade (derived) and Optum Health's goodwill rose from $6.3 billion to $42.8 billion (FY2016 and FY2025 10-K). Optum Health's growth was largely bought (inferred). UnitedHealthcare's was largely membership and pricing.

Growth drivers, ranked

5. Margin, cash & capital allocation

The margin is the gap between a premium fixed in advance and a cost known only later. One point of medical care ratio on 2025 premiums of $352.2 billion is about $3.5 billion of pre-tax earnings, nearly a fifth of 2025 earnings from operations (derived). The rest of the cost base is light. The operating cost ratio fell from 15.4% in 2016 to 13.3% in 2025, and capex runs at about 0.8% of revenue, mostly software (10-Ks, derived). Almost every cost is variable, so earnings are not wrecked by fixed-cost deleverage but by a few points of mispriced trend.

2025 showed the size of that lever. Medicare Advantage trend ran about 7.5% against bids built on "just over 5%". UnitedHealthcare absorbed about $6.5 billion more medical cost than planned, and Optum Health earned about $6.6 billion less than expected (Q2 2025 call). The medical care ratio rose to 89.1% from 85.5% and earnings from operations fell 41% to $19.0 billion (FY2025 10-K). Optum Health was hit twice, because its capitation is a share of the same MA premium that the V28 risk model cut. Its value-based margin fell to about 1% from about 5% in 2023 (Q3 2025 call).

Reserve releases now flatter results. Favourable prior-year development was $140 million in 2025, the lowest of the decade, then $1.25 billion in H1 2026, which the 10-Q attributes to a mild respiratory season. Management calls its $19.50–20.00 EPS guide "the right stepping off point, albeit it reflects prior period development" (Q2 2026 call).

Cash conversion is strong because claims are paid after premiums arrive: 2025 operating cash flow was $19.7 billion on $12.1 billion of net earnings (FY2025 10-K). Cash at the top company is thin, though. Of $24.4 billion of cash at end-2025, only about $1.1 billion was available for general corporate use. Regulated subsidiaries, which paid the parent $9.2 billion of net dividends in 2024, needed a net $535 million capital injection in 2025 as higher claims raised required capital (FY2024 and FY2025 10-K). Dividends and buybacks depend on subsidiary margins recovering.

From 2016 to 2025 UnitedHealth generated $201.3 billion of operating cash. It spent $80.0 billion on acquisitions, $51.6 billion on buybacks, $50.4 billion on dividends and $25.7 billion on capex, 103% of operating cash, and debt rose $45.4 billion to $78.4 billion (derived from 10-Ks). Buybacks cut the diluted share count by only 5.9%, to 911 million, because shares were bought at rising prices and issued for compensation and deals (derived). Acquisitions ranked first: management used insurance cash to build Optum, and goodwill rose from $47.6 billion to $110.5 billion (FY2016 and FY2025 10-K).

The new team has turned conservative. Buybacks stopped after early 2025 while debt-to-capital came down from 44.1% (Q3 2025) to 41.2% at June 2026, against a target of about 40% (Q3 2025 and Q2 2026 calls). With leverage near target, the 2026 buyback plan rose from $2.5 billion to at least $5 billion, executed at an average $344 a share in H1 (Q2 2026 call and 10-Q). The dividend kept rising, to $9.28 a year from June 2026.

6. Cyclicality, constraints & what to monitor

Health care demand barely follows GDP. The cycle that matters is underwriting: insurers set premiums a year ahead, trend surprises them, margins compress, they reprice and cut benefits, and margins recover. The decade shows the pattern. UnitedHealth's medical care ratio ranged from 79.1% in 2020, when Covid deferred care, to 83.2% in 2023, then broke to 85.5% and 89.1%. Earlier, $815 million of losses on 2015 ACA exchange plans led to a near-total exchange exit in 2017 (FY2016 10-K). Commercial risk membership does follow employment, but it is only 8.2 million of 49.8 million members (FY2025 10-K).

Position now: cost is at the top of its range and repricing has begun. The 2025 medical care ratio was the decade's highest and the 4.2% operating margin its lowest. In H1 2026 the ratio fell to 85.3% and the operating margin rose to 7.6% (Q2 2026 10-Q), helped by $1.25 billion of reserve releases. Membership is shrinking by choice. The whole industry is at the same point: NAIC reports a 0.4% margin for 2025 and peers' benefit ratios sit near 90% [web]. Industry-wide margin compression has historically led to pricing discipline (inferred).

The downside case is trend staying near 10% while government rates do not follow. CMS raised 2027 MA payments 2.48% before risk-score trend [web: CMS], against the roughly 10% trend UnitedHealthcare priced for 2026. Medicaid eligibility cuts in 2025 legislation (CBO: about 10 million more uninsured by 2034 [web]) leave sicker members behind while states pay rates the company already calls insufficient (FY2025 10-K). Lapsed ACA subsidies cut exchange enrolment from 22.1 million to 19.2 million [web: KFF citing CMS]. The business would feel this as a higher medical care ratio on a smaller base with prices fixed for the year, which is what produced 2025.

7. Risks, unknowns & questions for deeper work

• Coding scrutiny reprices the MA book. Risk-adjusted payments rise with recorded diagnoses. The DOJ has made criminal and civil requests about UnitedHealth's Medicare practices (8-K, July 24, 2025), CMS and OIG have selected plans for RADV audits (FY2025 10-K), and the False Claims Act case the DOJ joined in 2017 remains open after the DOJ objected to a Special Master's recommendation in the company's favour (Q2 2026 10-Q). An outcome that limits home-visit or chart-review coding would cut revenue per member permanently and hit Optum Health's capitation at the same time. The filings give no scope, accrual or timetable.
• Integration becomes the liability. Nearly half of UnitedHealthcare's revenue goes to Optum. Rebate pass-through rules, state limits on PBM-owned pharmacies (Arkansas, Q1 2025 call) and scrutiny of insurer-owned physicians target exactly the internal transfer that lifts group margins. A forced separation or mandate would remove a margin layer, not just volume.
• Correlated exposure. UnitedHealthcare, Optum Health and Optum Rx all depend on MA funding (Q4 2025 call). In 2025 one funding change hit two segments. The segment structure overstates diversification.
• Thin parent cash. Because subsidiaries needed capital rather than paying dividends in 2025 (Section 5), a second bad pricing year would push dividends and buybacks onto debt while all three ratings sit on negative outlook (FY2025 10-K).
• Acquisition record at risk of write-down. Goodwill of $110.5 billion is 1.2 times UnitedHealth shareholders' equity of $94.1 billion (derived). Optum Health's $42.8 billion has never been impaired despite 2025 losses. An impairment would not cost cash, but it would mark down the record of how $80 billion was spent.
• Execution credibility. Guidance was cut in April 2025, suspended in May and reset in July. The 2023–25 performance shares paid nothing (2026 proxy). The new CEO's $60 million option grant vests on time, not on a performance or price hurdle (2026 proxy).
• Smaller items. IRS proposed transfer-pricing adjustments for 2017–2020, amount undisclosed (Q2 2026 10-Q). About $2.6 billion of Change Healthcare provider loans outstanding against a $799 million reserve (derived; FY2025 10-K).

These compound. A coding settlement, an MA rate below trend and a political move against integration would hit the insurer and Optum together, at a time when the parent has little free cash.

What the sources could not answer:

• Premium per member and medical cost per member, by product (derived here, not disclosed)
• Organic versus acquired revenue growth; prices paid for Amedisys and LHC Group
• Number of patients in value-based arrangements (last disclosed for 2020) and margin by contract cohort beyond call commentary
• Optum Rx retained rebate and spread economics
• Scope, stage and any accrual for the DOJ Medicare inquiries; RADV dollar exposure
• 2026 revenue guidance after January; full-year 2025 segment results on the 2026 basis
• Star ratings for payment year 2028; the 2028 CMS risk-model recalibration
• Dollar size of the IRS proposed adjustments

Before forming a thesis an investor would need a view on normal MA margins after V28, evidence that Optum Health's value-based cohorts reach the 6–8% target without reserve help, and some resolution of the DOJ inquiries.

8. Investor takeaways

• What it is: the largest U.S. health insurer, now 59% dependent on government programmes, wrapped around Optum, its own supplier of care, drugs and claims processing.
• The engine: about $976 of premium per risk member-month with roughly 89 cents of each premium dollar going to care in 2025, plus a second margin as half of that money flows through Optum.
• Main growth lever: repricing above medical trend in 2026–2027, then a return to MA and value-based care growth on a smaller, better-priced base.
• What could break it: coding or integration rules that permanently lower revenue per member while trend stays near 10%, with little cash at the parent to absorb it.
• Monitor: medical care ratio net of reserve releases, CMS rate notices and Stars, Optum Health's margin, and the DOJ inquiries.